Home / Market News / $MRK
fiscal.ai Corporate Catalyst Impact 85/100 ● negative

Merck & Co., Inc. Reports Q3 2026 Financial Results

Oct 28, 2026, 9:33 PM UTC · Primary ticker $MRK

Merck reported a narrower-than-expected non-GAAP loss per share for Q3 2026, primarily due to a significant charge from the Terns Pharmaceuticals acquisition. While the company raised its full-year revenue outlook, it simultaneously lowered its adjusted EPS guidance, reflecting the financial impact of the acquisition-related charges. This mixed guidance presents a complex picture for investors.

Merck & Co., Inc. reported a non-GAAP loss per share of $0.13, which was better than analyst expectations. However, this loss was largely due to a substantial $2.31 per-share charge related to the acquisition of Terns Pharmaceuticals. While the company showed confidence by raising its 2026 revenue outlook, the simultaneous lowering of adjusted EPS guidance due to the Terns-related charges creates a mixed signal for investors. This indicates that while the core business, particularly Keytruda, is performing well, the acquisition is having a significant short-term financial impact. Traders will need to weigh the long-term strategic benefits of the Terns acquisition against its immediate dilutive effects on earnings.

$MRK neutral Mixed Q3 results and guidance
$TERNS neutral Acquisition impact on Merck's financials
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.